| 16.8901 0.01 (0.06%) | 06-10 11:50 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 20.5 | 1-year : | 23.95 |
| Resists | First : | 17.55 | Second : | 20.5 |
| Pivot price | 15.17 |
|||
| Supports | First : | 14.74 | Second : | 13 |
| MAs | MA(5) : | 16.75 |
MA(20) : | 14.86 |
| MA(100) : | 12.34 |
MA(250) : | 11 |
|
| MACD | MACD : | 1.1 |
Signal : | 1 |
| %K %D | K(14,3) : | 83.6 |
D(3) : | 80.1 |
| RSI | RSI(14): 68.6 |
|||
| 52-week | High : | 18.67 | Low : | 4.35 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ FTRE ] has closed below upper band by 18.5%. Bollinger Bands are 49.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 17.36 - 17.43 | 17.43 - 17.48 |
| Low: | 15.92 - 16 | 16 - 16.06 |
| Close: | 16.76 - 16.88 | 16.88 - 16.98 |
Fortrea Holdings Inc. functions as a global contract research organization (CRO), concentrating on providing development services for biopharmaceutical products and medical devices. The company's operations are divided into two main segments: Clinical Services and Enabling Services. Its Clinical Services division offers support across the entire spectrum of clinical pharmacology and development. The Enabling Services segment, conversely, delivers patient access programs and cutting-edge clinical trial technology solutions, aiming to simplify complex randomization processes and optimize the supply of trial medications for its customers. Fortrea presents a range of engagement options, such as full-service provision, functional service provider (FSP) models, and hybrid structures. Additionally, its portfolio includes managing clinical trials from Phase I through IV, offering distinctive technology-powered trial solutions, and providing post-market approval services. The company's client base primarily consists of pharmaceutical, biotechnology, and medical device entities. Fortrea Holdings Inc. was founded in 2023 and has its headquarters in Durham, North Carolina.
Tue, 09 Jun 2026
FTRE: All director, auditor, and Say-on-Pay proposals were approved by requisite vote - TradingView
Mon, 08 Jun 2026
Fortrea: A Greater Recovery Priced In Here (NASDAQ:FTRE) - Seeking Alpha
Mon, 08 Jun 2026
Goldman Sachs Group Inc. Acquires 293,992 Shares of Fortrea Holdings Inc. $FTRE - MarketBeat
Wed, 03 Jun 2026
Fortrea (FTRE) COO covers RSU tax bill with mandated share sale - Stock Titan
Wed, 03 Jun 2026
Fortrea (FTRE) CFO sells 4,866 shares to cover RSU tax obligations - Stock Titan
Tue, 26 May 2026
FTRE - Finviz
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 95 (M) |
| Shares Float | 94 (M) |
| Held by Insiders | 0.8 (%) |
| Held by Institutions | 109.9 (%) |
| Shares Short | 9,490 (K) |
| Shares Short P.Month | 10,580 (K) |
| EPS | -4.81 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.05 |
| Profit Margin | -16.5 % |
| Operating Margin | 0.5 % |
| Return on Assets (ttm) | -0.1 % |
| Return on Equity (ttm) | -64.6 % |
| Qtrly Rev. Growth | -2.3 % |
| Gross Profit (p.s.) | 5.4 |
| Sales Per Share | 28.65 |
| EBITDA (p.s.) | 0.73 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 221 (M) |
| Levered Free Cash Flow | 286 (M) |
| PE Ratio | -3.54 |
| PEG Ratio | 0.3 |
| Price to Book value | 2.8 |
| Price to Sales | 0.59 |
| Price to Cash Flow | 7.27 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|